Trials / Conditions / HER2-negative Metastatic Breast Cancer

HER2-negative Metastatic Breast Cancer

11 registered clinical trials studyying HER2-negative Metastatic Breast Cancer — 2 currently recruiting.

Status	Trial	Sponsor	Phase
Not Yet Recruiting	Efficacy and Safety of a Two-week Dosing Regimen of Vinorelbine Combined with Liposomal Doxorubicin in the Tre NCT06653972	Wang Jiayu	Phase 2
Completed	Adaptive Therapy for Post-Second-Line Advanced Breast Cancer NCT06533722	Sun Yat-sen University	Phase 2
Recruiting	Combination of Abemaciclib and Endocrine Therapy in Hormone Receptor Positive HER2 Negative Locally Advanced o NCT05362760	Prof. Wolfgang Janni	Phase 4
Completed	A Dose-escalation Study of the Safety and Pharmacology of DAN-222 in Subjects With Metastatic Breast Cancer NCT05261269	Dantari, Inc.	Phase 1
Terminated	Chemotherapy Monitoring by ctDNA in HER2- Metastatic Breast Cancer NCT04720729	Institut Curie	Phase 2
Completed	Durvalumab and Eribulin in Her2-negative Metastatic Breast Cancer and Recurrent Ovarian Cancer NCT03430518	Amy Tiersten	Phase 1
Completed	Safety and Pharmacokinetics of Atezolizumab Combination Treatments in Participants With HER2-Positive and HER2 NCT02605915	Hoffmann-La Roche	Phase 1
Unknown	Pilot Study of Cabazitaxel and Paclitaxel in HER2 Negative Breast Cancer NCT03048942	University Hospitals Bristol and Weston NHS Foundation Trust	Phase 2
Completed	Ph 1 ADI-PEG 20 Plus Doxorubicin; Patients With HER2 Negative Metastatic Breast Cancer NCT01948843	Polaris Group	Phase 1
Completed	DETECT III - A Multicenter, Phase III Study to Compare Standard Therapy +/- Lapatinib in HER2-ve MBC-Patients NCT01619111	Prof. Wolfgang Janni	Phase 3
Completed	Study to Compare Vinorelbine In Combination With the mTOR Inhibitor Everolimus vs. Vinorelbin Monotherapy for NCT01520103	AIO-Studien-gGmbH	Phase 2